Zhiwei Biopharma

Zhiwei Biopharma is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of next-generation radiopharmaceuticals. The company leverages its proprietary nanobody-based platform to create radionuclide-conjugated drugs (RDCs) for both diagnostic imaging and targeted therapy in oncology. Its lead candidate, SMT-01, is a 68Ga-labeled nanobody targeting PD-L1 for PET imaging to predict immunotherapy response. Zhiwei Biopharma aims to provide precision medicine solutions through a theranostic approach, integrating diagnosis and treatment for various solid tumors. The company's pipeline includes several candidates targeting FAP, PSMA, and other validated oncology markers. With a focus on nanobody technology, Zhiwei seeks to overcome the limitations of traditional antibody-based radiopharmaceuticals, such as slow blood clearance and high background noise.